Market Overview

UPDATE: Morgan Stanley Initiates Infinity Pharmaceuticals at Overweight on Blood Cancer Drug Data

Related INFI
Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma
New Biotech Pair Trade: Infinity Pharma Over ImmunoGen

Morgan Stanley initiated Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $47.00 price target.

Morgan Stanley noted, "Infinity's wholly-owned early stage IPI-145 for blood cancers has shown positive early data and is on track to figure significantly in an emerging BCR drug class with multi-billion dollar potential. 2013 holds multiple catalysts to further validate IPI-145's efficacy/safety."

Infinity Pharmaceuticals closed at $35.20 on Friday.

Latest Ratings for INFI

Sep 2015Morgan StanleyUpgradesEqual-weightOverweight
May 2015Deutsche BankInitiates Coverage onBuy
Jan 2015Morgan StanleyDowngradesOverweightEqualweight

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Analyst Ratings


Related Articles (INFI)

View Comments and Join the Discussion!

Get Benzinga's Newsletters